Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent or Metastatic Cervical Cancer

Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of December 16, 2021.